光学基因组图谱提高急性髓系白血病患者分类、风险分层和个体化治疗策略的准确性
该研究纳入159例急性髓系白血病患者(103例新诊断、56例难治/复发),所有患者均接受染色体显带分析、荧光原位杂交和靶向二代测序,评估光学基因组图谱的临床效用。OGM对SCG检测到的临床相关细胞遗传学异常灵敏度>99%(克隆负荷>20%时),并在77例(48%)患者中检出额外异常或融合基因信息。24例(15%)异常仅由OGM检出,可能改变AML分类、风险分层和/或临床试验资格。
要点
- OGM对克隆负荷>20%的临床相关细胞遗传学异常灵敏度>99%。
- 77例(48%)患者经OGM检出额外细胞基因组异常和/或融合基因信息。
- 24例(15%)异常仅由OGM检出,可能改变分类、风险分层或试验资格。
核心结论
- OGM是识别融合基因和检测CBA可能漏检的细微或隐匿性细胞基因组异常的有力工具。
研究设计与样本
- 研究纳入159例AML患者(103例新诊断和56例难治/复发),所有患者均接受染色体显带分析(CBA)、荧光原位杂交和靶向二代测序,并评估光学基因组图谱(OGM)的临床效用。
主要发现
- OGM对SCG检测到的几乎所有临床相关细胞遗传学异常灵敏度>99%,前提是克隆负荷>20%。
- OGM在77例(48%)患者中检出额外细胞基因组异常和/或提供融合基因信息,包括8例核型正常和4例核型分析失败的患者。
- OGM检出的最常见额外改变包括染色体碎裂(n=23)、KMT2A部分串联重复(n=11)、涉及MECOM的重排(n=7)、NUP98(n=2)、KMT2A(n=2)、JAK2(n=2)及其他基因融合17例,其中10例显示新的融合基因伴侣。
- OGM还在17例(11%)患者中精确定位了融合基因,这些患者同时经OGM和CBA检测到染色体重排。
- 共有24例(15%)异常仅由OGM检出,并可能改变AML分类、风险分层和/或临床试验资格。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytogenomic characterization is crucial for the classification and risk stratification of acute myeloid leukemia (AML), thereby facilitating therapeutic decision-making. We examined the clinical utility of optical genome mapping (OGM) in 159 AML patients (103 newly diagnosed and 56 refractory/relapsed), all of whom also underwent chromosomal banding analysis (CBA), fluorescence in situ hybridization, and targeted next-generation sequencing. OGM detected nearly all clinically relevant cytogenetic abnormalities that SCG identified with >99% sensitivity, provided the clonal burden was above 20%. OGM identified additional cytogenomic aberrations and/or provided information on fusion genes in 77 (48%) patients, including eight patients with normal karyotypes and four with failed karyotyping. The most common additional alterations identified by OGM included chromoanagenesis (n = 23), KMT2A partial tandem duplication (n = 11), rearrangements involving MECOM (n = 7), NUP98 (n = 2), KMT2A (n = 2), JAK2 (n = 2), and other gene fusions in 17 patients, with 10 showing novel fusion gene partners. OGM also pinpointed fusion genes in 17 (11%) patients where chromosomal rearrangements were concurrently detected by OGM and CBA. Overall, 24 (15%) aberrations were identified exclusively by OGM and had the potential to alter AML classification, risk stratification, and/or clinical trial eligibility. OGM emerges as a powerful tool for identifying fusion genes and detecting subtle or cryptic cytogenomic aberrations that may otherwise remain undetectable by CBA.
引用
- Loghavi S, Wei Q, Ravandi F, et al. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol. 2024. PMID: 39016111. doi:10.1002/ajh.27435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。